mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
about
Preclinical Murine Models for Lung Cancer: Clinical Trial ApplicationsGene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancerDevelopment and characterization of a novel in vivo model of carcinoid syndromeEradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach.Characterization of the canine mda-7 gene, transcripts and expression patterns.Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma.mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity.MDA-7/IL-24 suppresses human ovarian carcinoma growth in vitro and in vivo.Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in RatThe effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy.MDA-7/IL-24: multifunctional cancer killing cytokineVirotherapy, gene transfer and immunostimulatory monoclonal antibodies.Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo.Interferon-α enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma.Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.Targeted drug and gene delivery systems for lung cancer therapy.MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity.Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR.
P2860
Q26863474-C3560917-9355-4E8A-A28B-71FE3837B330Q30484735-A3FE22E7-4CE2-44AA-9CA6-231D244846E4Q30488738-59D2FC56-E0FD-45EF-A6D6-635235FA5CC1Q33730689-63A7F564-B017-4357-88AF-F71ED19491B2Q34040220-3606ED6E-2979-422B-A63C-0B562B783B62Q34582504-A4EE1AFE-0A4A-41A1-8076-534F28A5A87BQ35189796-B77DFB02-9955-4CFF-A356-5F078D3E2121Q35633270-8ADDD60B-0C10-4055-9B5B-A9401E92F376Q35961353-0240DBF7-0962-4F74-BE15-5A2427B66F13Q36172732-642AEAE7-76CA-4265-BEC0-D5C2B8DD1153Q36244267-849666F2-2CFD-49F2-90EC-683504F4E63CQ36248193-65EDBB70-83B7-4D87-8C83-CF01DEBCD48AQ36456487-48142E92-E2D2-488F-9594-CC2A6731F9D2Q36485293-70528FD3-B50A-450A-84E0-D29C802083F9Q36971961-E34F85EE-E119-4F94-A6A1-471B2184C4C0Q39357711-0336022C-9B04-4762-A466-1C7660A8B723Q39773632-9646E2C4-F7AD-4A3F-A96E-0D5063312437Q40082930-9C230151-EFC3-4368-81BF-A6DDCBE2E06CQ40176991-E9DE470A-0E70-4C8D-B688-B9773495E7BD
P2860
mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
mda-7 In combination with beva ...... ffect on lung tumor xenograft.
@en
type
label
mda-7 In combination with beva ...... ffect on lung tumor xenograft.
@en
prefLabel
mda-7 In combination with beva ...... ffect on lung tumor xenograft.
@en
P2093
P356
P1433
P1476
mda-7 In combination with beva ...... ffect on lung tumor xenograft.
@en
P2093
Amanda Hartman
Benjamin N Bekele
Corazan D Bucana
Cynthia D Branch
L Clifton Stephens
Rajagopal Ramesh
Satoshi Inoue
Sunil Chada
P304
P356
10.1038/SJ.MT.6300035
P577
2007-02-01T00:00:00Z